STUDY OF CHANGES IN APPENDIX 3 OF THE POSITIVE DRUG LIST IN BULGARIA

Abstract

The public nature of health care obliges the state to conduct a consistent policy that aims to ensure the protection of human health with optimal use of public funds. Achieving better management in the health care system is in the interest of individuals and society as a whole. And decisions in health care, as in any other area of human activity, must be economically rational, since all economic goods, including those related to health care, are limited in nature.
The medicinal products included in Appendix 3 of the Positive Drug List have a reimbursement level of 100% and are negotiated and paid for from the budget of the Ministry of Health. These are medicinal products intended for the treatment of AIDS, infectious diseases, diseases outside the scope of the Health Insurance Act, paid according to a certain order of the Health Act, as well as vaccines for mandatory immunizations and re-immunizations, vaccines for special indications and in emergencies circumstances, specific sera, immunoglobulins.
The purpose of the present study is to perform a comparative analysis of the changes in the reference values of the medicinal products included in Appendix 3 of the Positive Drug List.
Methodology: The following research methods were used - documentary method, economic analysis, comparative analysis, statistical methods - analysis of the dynamics of phenomena and tabular analysis to visualize the obtained results.
Results and analysis: From the research done, it is clear that for the period 2016-2019 only a decrease was observed, while for 2020 there was also an increase in the reference values of some medicinal products included in Appendix 3 of the Positive Drug List, the reasons for this being exclusion of a medicinal product from the list, increase in the price of a medicinal product and new grouping of medicinal products by therapeutic indication.
Conclusion: Medicines are of fundamental importance in maintaining life, improving its quality and alleviating suffering. This determines the need to ensure equal access to medicinal products for citizens, according to their needs and regardless of their financial capabilities.